Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Top Page
Aptevo Therapeutics
(NASDAQ:APVO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▲(637.70% Upside)
Action:ReiteratedDate:03/27/26
The score is weighed down primarily by very weak financial performance (no revenue in 2023–2025 and heavy ongoing cash burn) and bearish technicals (price below major moving averages with negative MACD). Offsetting factors include positive corporate developments (encouraging interim AML data and improved access to financing), though the financing path increases dilution risk and valuation is not compelling due to losses and no dividend.
Positive Factors
Promising AML trial data
The interim RAINIER data showing high clinical benefit, deep remissions and no cytokine release syndrome suggests mipletamig may offer a differentiated safety-efficacy profile in elderly/unfit AML. If confirmed in later trials, this durable clinical differentiation supports long-term combinability and market positioning versus current standards of care.
Negative Factors
Zero revenue and persistent losses
Having no revenue over multiple years and persistent operating losses means Aptevo lacks commercial cash inflows to underwrite operations. This structural dependence on successful clinical outcomes or external capital increases solvency risk: failure to achieve pivotal milestones would materially worsen funding stress and strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising AML trial data
The interim RAINIER data showing high clinical benefit, deep remissions and no cytokine release syndrome suggests mipletamig may offer a differentiated safety-efficacy profile in elderly/unfit AML. If confirmed in later trials, this durable clinical differentiation supports long-term combinability and market positioning versus current standards of care.
Read all positive factors
Aptevo Therapeutics (APVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.25M
Dividend YieldN/A
Average Volume (3M)11.64M
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS Growth99.02%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1684.47
Shares Outstanding1,181,725
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit113.76
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.99
Revenue Forecast (FY)N/A
Aptevo Therapeutics Business Overview & Revenue Model
Company Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell eng...
How the Company Makes Money
null...
Aptevo Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 3.11M | 12.29M |
| Gross Profit | -240.00K | -352.00K | 0.00 | 3.11M | 12.29M |
| EBITDA | -26.07M | -23.78M | -28.31M | -27.74M | -20.26M |
| Net Income | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M |
Balance Sheet | |||||
| Total Assets | 27.19M | 15.59M | 24.84M | 34.22M | 56.60M |
| Cash, Cash Equivalents and Short-Term Investments | 21.62M | 8.71M | 16.90M | 22.64M | 45.04M |
| Total Debt | 4.63M | 4.63M | 5.40M | 9.54M | 16.71M |
| Total Liabilities | 9.81M | 10.84M | 12.62M | 16.24M | 55.38M |
| Stockholders Equity | 17.38M | 4.75M | 12.22M | 17.97M | 1.22M |
Cash Flow | |||||
| Free Cash Flow | -25.59M | -23.79M | -11.73M | -21.05M | -22.39M |
| Operating Cash Flow | -25.59M | -23.79M | -11.73M | -21.02M | -21.68M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -29.00K | -713.00K |
| Financing Cash Flow | 38.50M | 15.60M | 6.00M | -2.62M | 26.16M |
Aptevo Therapeutics Technical Analysis
Negative
0.61
Price Trends
5.73
Negative
10.93
Negative
23.83
Negative
Market Momentum
-0.50
Negative
40.53
Neutral
66.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Negative. The current price of 0.61 is below the 20-day moving average (MA) of 4.37, below the 50-day MA of 5.73, and below the 200-day MA of 23.83, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 40.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APVO.
Aptevo Therapeutics Risk Analysis
Aptevo Therapeutics disclosed 58 risk factors in its most recent earnings report. Aptevo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptevo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $45.25M | -0.97 | -84.39% | ― | ― | 15.32% | |
52 Neutral | $46.08M | -1.26 | -55.75% | ― | ― | 30.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $13.98M | -1.17 | ― | ― | ― | 79.31% | |
44 Neutral | $5.25M | >-0.01 | -389.34% | ― | ― | 99.02% | |
41 Neutral | $20.09M | -1.15 | -112.05% | ― | ― | 99.82% |
* Healthcare Sector Average
APVO
Aptevo Therapeutics
4.44
-369.96
-98.81%
LSTA
Lisata Therapeutics
5.01
3.05
155.61%
MBRX
Moleculin Biotech
2.62
-18.11
-87.36%
EDSA
Edesa Biotech
5.52
3.14
131.93%
ALLR
Allarity Therapeutics
1.27
0.55
76.39%
Aptevo Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Aptevo Reports Promising Interim Data for AML Therapy
Positive
Mar 11, 2026
On March 10, 2026, Aptevo Therapeutics reported new interim data from two trials of its lead candidate mipletamig, used in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are elderly or unfit for ...
Private Placements and FinancingShareholder Meetings
Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity
Positive
Feb 19, 2026
On February 18, 2026, Aptevo Therapeutics Inc. held a special meeting of stockholders at which investors rejected technical and administrative amendments to the company’s Amended and Restated Certificate of Incorporation, reflecting insuffic...
Business Operations and StrategyExecutive/Board Changes
Aptevo Therapeutics Announces CEO Transition and Leadership Changes
Positive
Feb 3, 2026
On February 3, 2026, Aptevo Therapeutics announced that President and Chief Executive Officer Marvin White, who has led the company since 2016, will retire from the CEO role effective April 1, 2026, becoming Executive Chair while current Chief Ope...
Business Operations and StrategyPrivate Placements and Financing
Aptevo Therapeutics Secures $60 Million Equity Financing Facility
Positive
Jan 9, 2026
On January 8, 2026, Aptevo Therapeutics entered into a $60 million standby equity purchase and equity line of credit arrangement with Yorkville Advisors, giving the company the right, but not the obligation, to sell common shares over 36 months un...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Aptevo Therapeutics Implements 1-for-18 Reverse Stock Split
Neutral
Dec 29, 2025
On July 24, 2025, Aptevo Therapeutics’ stockholders approved a range of potential reverse stock split ratios, after which the board on December 17, 2025 selected a 1-for-18 ratio and filed an amendment to the company’s certificate of i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.